ImmunAdd Inc.
Update：2024/07/15
Industries
Main Industry
Biotechnology
Main Product/Service
ImmunAdd develops innovative and practical solutions for human health. We aim to harness the immune system to create next-generation immunotherapeutics for the treatment of infectious diseases and cancer. Our next-generation adjuvants provide better immune activities in combination with anti-infection and anti-cancer vaccines. ImmunAdd has developed an efficient and sustainable manufacturing process for IA-05. With POC purpose, ImmunAdd will continue to expand our development to clinical-stage programs.
Founded Year
2022
Unified Business No.
90379709
Status
Active
Number of Employees
15
Total Paid-in
Capital
213,000,000 (NT$)
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, Ministry of Economic Affairs.
Location of Company
Taiwan
, Taipei City
Exclusive content for members
Members-only content. Please log in to access.
Introduction
Dedicated to enhancing human health and well-being, ImmunAdd is a biotech pharmaceutical research and development company focused on drug design and formulation development. Our team members have accumulated years of experience in medicinal chemistry, drug formulation, drug regulations, biological animal evaluation, and clinical trials. With our specialized knowledge in drug development, we aim to address the urgent needs in drug therapy and contribute to human health. Our pipeline covers vaccine adjuvant development, new formulation development, and novel drug conjugation strategies applied in vaccines, cancer, and immunotherapies.
ImmunAdd Inc. was established in 2022 as a start-up biotechnology company from National Taiwan University, founded by Professor Pi-Hui Liang and scientists with years of experience in pharmaceutical and industrial sectors.
ImmunAdd Inc. was established in 2022 as a start-up biotechnology company from National Taiwan University, founded by Professor Pi-Hui Liang and scientists with years of experience in pharmaceutical and industrial sectors.
